Clinical validation of coexisting driver mutations in colorectal cancers

Gang Zheng, Li Hui Tseng, Lisa Haley, Junaid Ibrahim, Jennifer Bynum, Rena Xian, Christopher Gocke, James Eshleman, Ming-Tseh Lin

Research output: Contribution to journalArticle

Abstract

Mutational profiling is recommended for selecting targeted therapy and predicting prognosis of metastatic colorectal cancer (CRC). Detection of coexisting mutations within the same pathway, which are usually mutually exclusive, raises the concern for potential laboratory errors. In this retrospective study for quality assessment of a next-generation sequencing assay, we examined BRAF, KRAS, and NRAS genes within the mitogen-activated protein kinase (MAPK) pathway and the PIK3CA gene within the phosphatidylinositol 3-kinase (mTOR) pathway in 744 CRC specimens submitted to our clinical diagnostics laboratory. Although coexistence of mutations between the MAPK and mTOR pathways was observed, it rarely occurred within the MAPK pathway. Retrospective quality assessments identified false detection of coexisting activating KRAS and NRAS mutations in 1 specimen and confirmed 2 activating KRAS mutations in 2 specimens and coexisting activating KRAS and NRAS mutations in 2 specimens, but no coexisting activating RAS and BRAF mutations. There were 15 CRCs with a kinase-impaired BRAF mutation, including 3 with a coexisting activating KRAS mutation, which may have therapeutic implications. Multiregional analysis based on different histologic features demonstrated that coexisting KRAS and NRAS mutations may be present in the same or different tumor populations and showed that invasion of adenomas by synchronous adenocarcinomas of different clonal origin may result in detection of coexisting mutations within the MAPK pathway. In this study, we proposed an operating procedure for clinical validation of unexpected coexisting mutations. Further studies are warranted to elucidate the biological significance and clinical implications of coexisting mutations within the MAPK pathway.

Original languageEnglish (US)
Pages (from-to)12-20
Number of pages9
JournalHuman pathology
Volume86
DOIs
StatePublished - Apr 1 2019

Fingerprint

Colorectal Neoplasms
Mutation
Mitogen-Activated Protein Kinases
Proto-Oncogene Proteins B-raf
Phosphatidylinositol 3-Kinase
Adenoma
Genes
Adenocarcinoma
Retrospective Studies
Demography
Therapeutics

Keywords

  • BRAF
  • Coexisting mutation
  • Colorectal cancer
  • KRAS
  • NRAS
  • PIK3CA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Clinical validation of coexisting driver mutations in colorectal cancers. / Zheng, Gang; Tseng, Li Hui; Haley, Lisa; Ibrahim, Junaid; Bynum, Jennifer; Xian, Rena; Gocke, Christopher; Eshleman, James; Lin, Ming-Tseh.

In: Human pathology, Vol. 86, 01.04.2019, p. 12-20.

Research output: Contribution to journalArticle

Zheng, Gang ; Tseng, Li Hui ; Haley, Lisa ; Ibrahim, Junaid ; Bynum, Jennifer ; Xian, Rena ; Gocke, Christopher ; Eshleman, James ; Lin, Ming-Tseh. / Clinical validation of coexisting driver mutations in colorectal cancers. In: Human pathology. 2019 ; Vol. 86. pp. 12-20.
@article{dd5c0c8ba6474eb485599e38d802e91a,
title = "Clinical validation of coexisting driver mutations in colorectal cancers",
abstract = "Mutational profiling is recommended for selecting targeted therapy and predicting prognosis of metastatic colorectal cancer (CRC). Detection of coexisting mutations within the same pathway, which are usually mutually exclusive, raises the concern for potential laboratory errors. In this retrospective study for quality assessment of a next-generation sequencing assay, we examined BRAF, KRAS, and NRAS genes within the mitogen-activated protein kinase (MAPK) pathway and the PIK3CA gene within the phosphatidylinositol 3-kinase (mTOR) pathway in 744 CRC specimens submitted to our clinical diagnostics laboratory. Although coexistence of mutations between the MAPK and mTOR pathways was observed, it rarely occurred within the MAPK pathway. Retrospective quality assessments identified false detection of coexisting activating KRAS and NRAS mutations in 1 specimen and confirmed 2 activating KRAS mutations in 2 specimens and coexisting activating KRAS and NRAS mutations in 2 specimens, but no coexisting activating RAS and BRAF mutations. There were 15 CRCs with a kinase-impaired BRAF mutation, including 3 with a coexisting activating KRAS mutation, which may have therapeutic implications. Multiregional analysis based on different histologic features demonstrated that coexisting KRAS and NRAS mutations may be present in the same or different tumor populations and showed that invasion of adenomas by synchronous adenocarcinomas of different clonal origin may result in detection of coexisting mutations within the MAPK pathway. In this study, we proposed an operating procedure for clinical validation of unexpected coexisting mutations. Further studies are warranted to elucidate the biological significance and clinical implications of coexisting mutations within the MAPK pathway.",
keywords = "BRAF, Coexisting mutation, Colorectal cancer, KRAS, NRAS, PIK3CA",
author = "Gang Zheng and Tseng, {Li Hui} and Lisa Haley and Junaid Ibrahim and Jennifer Bynum and Rena Xian and Christopher Gocke and James Eshleman and Ming-Tseh Lin",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.humpath.2018.11.014",
language = "English (US)",
volume = "86",
pages = "12--20",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Clinical validation of coexisting driver mutations in colorectal cancers

AU - Zheng, Gang

AU - Tseng, Li Hui

AU - Haley, Lisa

AU - Ibrahim, Junaid

AU - Bynum, Jennifer

AU - Xian, Rena

AU - Gocke, Christopher

AU - Eshleman, James

AU - Lin, Ming-Tseh

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Mutational profiling is recommended for selecting targeted therapy and predicting prognosis of metastatic colorectal cancer (CRC). Detection of coexisting mutations within the same pathway, which are usually mutually exclusive, raises the concern for potential laboratory errors. In this retrospective study for quality assessment of a next-generation sequencing assay, we examined BRAF, KRAS, and NRAS genes within the mitogen-activated protein kinase (MAPK) pathway and the PIK3CA gene within the phosphatidylinositol 3-kinase (mTOR) pathway in 744 CRC specimens submitted to our clinical diagnostics laboratory. Although coexistence of mutations between the MAPK and mTOR pathways was observed, it rarely occurred within the MAPK pathway. Retrospective quality assessments identified false detection of coexisting activating KRAS and NRAS mutations in 1 specimen and confirmed 2 activating KRAS mutations in 2 specimens and coexisting activating KRAS and NRAS mutations in 2 specimens, but no coexisting activating RAS and BRAF mutations. There were 15 CRCs with a kinase-impaired BRAF mutation, including 3 with a coexisting activating KRAS mutation, which may have therapeutic implications. Multiregional analysis based on different histologic features demonstrated that coexisting KRAS and NRAS mutations may be present in the same or different tumor populations and showed that invasion of adenomas by synchronous adenocarcinomas of different clonal origin may result in detection of coexisting mutations within the MAPK pathway. In this study, we proposed an operating procedure for clinical validation of unexpected coexisting mutations. Further studies are warranted to elucidate the biological significance and clinical implications of coexisting mutations within the MAPK pathway.

AB - Mutational profiling is recommended for selecting targeted therapy and predicting prognosis of metastatic colorectal cancer (CRC). Detection of coexisting mutations within the same pathway, which are usually mutually exclusive, raises the concern for potential laboratory errors. In this retrospective study for quality assessment of a next-generation sequencing assay, we examined BRAF, KRAS, and NRAS genes within the mitogen-activated protein kinase (MAPK) pathway and the PIK3CA gene within the phosphatidylinositol 3-kinase (mTOR) pathway in 744 CRC specimens submitted to our clinical diagnostics laboratory. Although coexistence of mutations between the MAPK and mTOR pathways was observed, it rarely occurred within the MAPK pathway. Retrospective quality assessments identified false detection of coexisting activating KRAS and NRAS mutations in 1 specimen and confirmed 2 activating KRAS mutations in 2 specimens and coexisting activating KRAS and NRAS mutations in 2 specimens, but no coexisting activating RAS and BRAF mutations. There were 15 CRCs with a kinase-impaired BRAF mutation, including 3 with a coexisting activating KRAS mutation, which may have therapeutic implications. Multiregional analysis based on different histologic features demonstrated that coexisting KRAS and NRAS mutations may be present in the same or different tumor populations and showed that invasion of adenomas by synchronous adenocarcinomas of different clonal origin may result in detection of coexisting mutations within the MAPK pathway. In this study, we proposed an operating procedure for clinical validation of unexpected coexisting mutations. Further studies are warranted to elucidate the biological significance and clinical implications of coexisting mutations within the MAPK pathway.

KW - BRAF

KW - Coexisting mutation

KW - Colorectal cancer

KW - KRAS

KW - NRAS

KW - PIK3CA

UR - http://www.scopus.com/inward/record.url?scp=85061910904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061910904&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2018.11.014

DO - 10.1016/j.humpath.2018.11.014

M3 - Article

C2 - 30481508

AN - SCOPUS:85061910904

VL - 86

SP - 12

EP - 20

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -